Trial Profile
Tumor volume analysis of ALK-rearranged advanced non-small-cell-lung-cancer treated with crizotinib to identify an early imaging marker that can predict clinical outcome.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Oct 2018
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 11 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer